Hypertension Screening and Treatment Program

This study has been completed.
Sponsor:
Information provided by:
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00007592
First received: December 29, 2000
Last updated: January 20, 2009
Last verified: February 2003
  Purpose

Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.


Condition Intervention
Hypertension
Drug: Chlorthalidone
Drug: Furosemide

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: VA HYPERTENSION SCREENING AND TREATMENT PROGRAM (PILOT STUDY)

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Study Start Date: June 1989
Detailed Description:

Primary Hypothesis: A variety of clinical questions of major importance can be addressed using clinical data routinely obtained in the VA Hypertension Screening and Treatment Program. For example, treatment of mild hypertension reduces the risk of strokes and heart attacks.

Secondary Hypothesis: Target organ damage occurs despite blood pressure control.

Intervention: Chlorthalidone, furosemide, hydrochlorothiazide, metolazone, indapamide, amiloride, spironolactone, triamterene, atenolol, metoprolol, nadolol, pindolol, propranolol, timolol, acebutolol, penbutolol, clonidine, guanethidine, methydopa, prazosin, guanadrel, labetalol, reserpine, guanfacine, hydralazine, minoxidil, captopril, enalapril, lisinopril, diltiazem, nifedipine, verapamil, nicardipine, dyazide, maxzide, pargyline, terazosin, other anti-hypertensives.

Primary Outcomes: Blood Pressure and Target Organ Damage

Study Abstract: Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.

This demonstration project provides for central collection of a standard set of clinical data for patients at some of the Hypertension Screening and Treatment Program clinics, thereby setting up a national data base on the treatment of hypertension. The primary objective of this project is to demonstrate the value of establishing this type of database. The database is being used to estimate the average annual cost of different antihypertensive regimens, to determine the cost-efficacy of different therapies and the least expensive effective therapy and to address some major unanswered clinical questions that require large populations and long-term patient care data. There are currently 13 medical centers participating.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Patients at Hypertension Screening and Treatment Program clinics

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00007592

Locations
United States, California
Vamc - Sepulveda
Sepulveda, California, United States
United States, District of Columbia
Vamc - Washington, Dc
Washington, District of Columbia, United States
United States, Florida
Vamc - Miami
Miami, Florida, United States
United States, Indiana
Vamc - Indianapolis
Indianapolis, Indiana, United States
United States, Iowa
Vamc - Iowa City
Iowa City, Iowa, United States
United States, Mississippi
Vamc - Jackson
Jackson, Mississippi, United States
United States, Ohio
Vamc - Dayton
Dayton, Ohio, United States
United States, Pennsylvania
Vamc - Philadelphia
Philadelphia, Pennsylvania, United States
Vamc - Pittsburgh
Pittsburgh, Pennsylvania, United States
United States, Tennessee
Vamc - Memphis
Memphis, Tennessee, United States
United States, Virginia
Vamc - Richmond
Richmond, Virginia, United States
Puerto Rico
Vamc - San Juan, Pr
San Juan, Puerto Rico
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00007592     History of Changes
Other Study ID Numbers: 324
Study First Received: December 29, 2000
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Hypertension
national data base on the treatment of hypertension
cost of different antihypertensive regimens

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Chlorthalidone
Furosemide
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors

ClinicalTrials.gov processed this record on April 21, 2014